Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.60 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.60 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.60 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.60 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.60 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.60 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.60 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 6/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL830378 | 0.89 | ALDH1A1 (0.71) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL830073 | 0.87 | KDM4E (0.54) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1259124 | 0.87 | KDM4E (0.61) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL26213303 | 0.86 | KMT2A (0.56) | KDM4EALDH1A1MAPTRAB9AGAA | |
| SCHEMBL829181 | 0.86 | ALDH1A1 (0.66) | KDM4EALDH1A1MAPTRAB9AGAA | |
| SCHEMBL333983 | 0.86 | ALDH1A1 (0.53) | GABRA1GABRA3KDM4EALDH1A1MAPT | |
| SCHEMBL27385781 | 0.84 | GABRA1 (0.44) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7086632 | 0.83 | ALDH1A1 (0.58) | KDM4EALDH1A1MAPTRAB9AGAA | |
| SCHEMBL2724382 | 0.82 | KDM4E (0.63) | KDM4EALDH1A1MAPTRAB9AGAA | |
| SCHEMBL30797259 | 0.82 | KDM4E (0.63) | KDM4EALDH1A1MAPTRAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2731948-B1 | NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICALS INC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-9115143-B2 | Substituted indole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115143-B2 | Substituted indole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140148450-A1 | NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | disclosed |
| US-20140148450-A1 | NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | disclosed |
| WO-2013010904-A1 | NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | Janssen Pharmaceuticals, Inc. (US) | 2013-01-24 | — | — | WO | disclosed |
| US-8008295-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| EP-1534695-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| US-20090186871-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-07-23 | — | — | US | disclosed |
| EP-1534695-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20080008708-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
| EP-1534268-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060128783-A1 | Tyrosine kinase inhibitors | DINSMORE CHRISTOPHER J | 2006-06-15 | — | — | US | disclosed |
| US-20050261496-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2005-11-24 | — | — | US | disclosed |
| EP-1534268-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-1534695-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040102360-A1 | Combination therapy | BARNETT STANLEY F (US) | 2004-05-27 | — | — | US | disclosed |
| WO-2004014851-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014300-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148450-A1 | NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APP | GABRA1 857/4885GABRG2 821/4885GABRB3 255/4885 |
| US-20060128783-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, JAK2 | GABRA1 1256/4885GABRG2 1458/4885GABRB3 1776/4885 |
| US-20050261496-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | GABRA1 1230/4885GABRG2 1339/4885GABRB3 1567/4885 |
| US-20040102360-A1 | Combination therapy | MTOR, AKT2, PLK1 | GABRA1 4513/4885GABRG2 4280/4885GABRB3 4320/4885 |
| US-20080008708-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, JAK2 | GABRA1 1256/4885GABRG2 1458/4885GABRB3 1776/4885 |
| US-20090186871-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | GABRA1 1230/4885GABRG2 1339/4885GABRB3 1567/4885 |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, JAK2 | GABRA1 1256/4885GABRG2 1458/4885GABRB3 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.